Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases
"The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches.Buil...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Fight-nCoV
FIGHTING OFF CORONAVIRUS SARS CoV 2 WITH BROAD SPECTRUM AN...
3M€
Cerrado
APPEAL
Antivirus Pandemic Preparedness EuropeAn pLatform
8M€
Cerrado
HIV ACE
Targeting assembly of infectious HIV particles
5M€
Cerrado
PID2021-123888OB-I00
REDUCCION DEL TIEMPO DE DESARROLLO DE ANTIVIRALES ORALES MED...
109K€
Cerrado
SILVER
Small molecule Inhibitor Leads Versus emerging and neglected...
22M€
Cerrado
PID2019-105117RR-C22
NUEVOS ANTIVIRALES MEDIANTE DISEÑO BASADO EN LA ESTRUCTURA D...
229K€
Cerrado
Información proyecto AVITHRAPID
Duración del proyecto: 53 meses
Fecha Inicio: 2024-01-01
Fecha Fin: 2028-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches.Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses. This will be achieved by combining the relevant expertisefor pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus. Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets. As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases."